Sun Pharma Advanced Research Company's Q3 FY 2025-26 Quarterly Results
- 10 Feb 2026
Result Summary
- Sun Pharma Advanced Research Company Ltd reported a 7.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 44.0%.
- Its expenses for the quarter were down by 8.6% QoQ and 19.1% YoY.
- The net profit increased 6.0% QoQ and increased 1.1% YoY.
- The earnings per share (EPS) of Sun Pharma Advanced Research Company Ltd declined at 2.48 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 8.45 | 7.87 | 15.10 | 7.4% | -44.0% |
Total Expenses | 76.44 | 83.66 | 94.54 | -8.6% | -19.1% |
Profit Before Tax | -80.35 | -75.79 | -79.44 | 6.0% | 1.1% |
Tax | 0.07 | 0.06 | 0.07 | 16.7% | 0.0% |
Profit After Tax | -80.42 | -75.85 | -79.51 | 6.0% | 1.1% |
Earnings Per Share | -2.48 | -2.34 | -2.45 | 6.0% | 1.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sun Pharma Advanced Research Company Ltd (SPARC) operates predominantly within the pharmaceutical industry, focusing on advanced research and development. SPARC is an entity dedicated to the development of new chemical entities, novel drug delivery systems, and other innovations within the pharmaceutical sector. As an integral part of the larger Sun Pharmaceutical Industries, SPARC plays a critical role in pioneering cutting-edge treatments and drug formulations. Recent developments or significant changes in the company's strategic direction are not available from the provided data.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Sun Pharma Advanced Research Company Ltd reported a total income of ₹8.45 crores. This marks a quarter-over-quarter (QoQ) increase of 7.4% compared to ₹7.87 crores in Q2FY26. Year-over-year (YoY), the total income experienced a significant decline of 44.0% from ₹15.10 crores in Q3FY25. These figures highlight the fluctuations in revenue generation over the past periods.
Profitability
The company reported a Profit Before Tax (PBT) of -₹80.35 crores in Q3FY26, representing a 6.0% increase in losses compared to the previous quarter where the PBT was -₹75.79 crores. Compared to the same quarter in the previous year, the PBT decreased marginally by 1.1% from -₹79.44 crores. The tax expense for the quarter was ₹0.07 crores, consistent with the tax expense in Q3FY25 and showing a slight increase from ₹0.06 crores in Q2FY26. Consequently, the Profit After Tax (PAT) stood at -₹80.42 crores in Q3FY26, following the same percentage changes observed in PBT for both QoQ and YoY comparisons.
Operating Metrics
Key operating metrics such as Earnings Per Share (EPS) were reported at -₹2.48 for Q3FY26. This reflects a 6.0% increase in losses per share QoQ from -₹2.34 in Q2FY26, and a 1.2% increase YoY from -₹2.45 in Q3FY25. Total expenses for the quarter amounted to ₹76.44 crores, marking a decrease of 8.6% from ₹83.66 crores in Q2FY26, and a 19.1% decrease from ₹94.54 crores in Q3FY25. The data indicates a continued effort in cost management over the observed quarters.